GlassScriptPhysician profile
Kwan-Sian Chen
NPI 1619928025
$16,693.27
in general payments reported to CMS, 2019-2025
38 companies · $2,048 in 2025
The $2,048 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,252 · 2020: $1,743 · 2021: $1,972 · 2022: $4,051 · 2023: $2,304 · 2024: $2,324 · 2025: $2,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,282 · Education: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,282.30 |
| Education | $394.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,298.52 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Claria Mri Quad Crt-D Surescan |
| Actelion Pharmaceuticals US, INC. | $2,252.98 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $1,363.63 | 2019-2025 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $1,152.29 | 2019-2025 | |
| Boston Scientific Corporation | $982.19 | 2019-2025 | Watchman Flx, Intracept, Watchman Access System |
| Janssen Pharmaceuticals, INC | $886.88 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $758.26 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $738.41 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $705.03 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $643.79 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $604.46 | 2019-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $559.30 | 2019-2022 | |
| Amgen INC. | $499.94 | 2019-2025 | Repatha, Repatha |
| Biotronik INC. | $416.47 | 2020-2025 | Selectra, Acticor 7 Vr-T Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $363.65 | 2019-2025 | Lifevest |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $319.78 | 2019-2022 | |
| Abbott Laboratories | $313.37 | 2021-2025 | Assurity, Aveir, Amplatzer Amulet |
| Atricure, INC. | $260.57 | 2023-2024 | |
| Medtronic Vascular, INC. | $195.09 | 2020 | |
| Gilead Sciences, INC. | $188.33 | 2019 | |
| Esperion Therapeutics, INC. | $187.67 | 2020-2024 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $131.48 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $126.32 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Akcea Therapeutics, INC. | $124.99 | 2019 | |
| Abiomed | $124.99 | 2024 | Impella |
| Regeneron Healthcare Solutions, INC. | $119.81 | 2019 | |
| Edwards Lifesciences Corporation | $84.43 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Allergan, INC. | $44.83 | 2019 | |
| Arbor Pharmaceuticals, INC. | $41.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.54 | 2019 | |
| Ironwood Pharmaceuticals, INC | $32.55 | 2021 | |
| United Therapeutics Corporation | $27.05 | 2024 | Tyvaso |
| Alnylam Pharmaceuticals INC. | $25.32 | 2025 | Amvuttra |
| Baxter Healthcare | $23.13 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Kestra Medical Technology Services, INC. | $15.09 | 2024 | Assure Wcd |
| Radius Health, INC. | $14.57 | 2019 | |
| Medicomp INC | $14.41 | 2022 | |
| Chiesi USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kwan-Sian Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.